BioCentury
ARTICLE | Company News

Athersys, Healios expanding MultiStem deal

March 16, 2018 7:30 PM UTC

Athersys Inc. (NASDAQ:ATHX) and Healios K.K. (Tokyo:4593) entered into a letter of intent (LOI) to expand Healios' license to develop MultiStem products to include treatment of acute respiratory distress syndrome (ARDS) and trauma in Japan. Under the LOI, Healios would also gain worldwide rights to the MultiStem technology for use in conjunction with Healios’ “organ bud” technology and for undisclosed ophthalmologic indications. The expanded deal is expected to close April 30.

Under the expanded deal, Healios will make a $21 million equity investment in Athersys through the purchase of 12 million shares. Healios will also pay Athersys $25 million in license/options fees and receive a warrant to purchase additional Athersys shares until September 2020...

BCIQ Company Profiles

Athersys Inc.

Healios K.K.